HALOZYME THERAPEUTICS, INC.

(HALO)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
46.90 USD   +0.21%
06/15TRANSCRIPT : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 08:00 AM
CI
06/10Genmab Seeks $405 Million in New Arbitration With Janssen
MT
06/10Genmab Opens New Arbitration In Daratumumab License Dispute With Janssen
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/17/2022 06/21/2022 06/22/2022 06/23/2022 06/24/2022 Date
44.14(c) 45.76(c) 45.9(c) 46.8(c) 46.9(c) Last
2 395 696 884 739 959 114 1 310 956 3 186 782 Volume
+2.39% +3.67% +0.31% +1.96% +0.21% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 715 M - -
Net income 2022 279 M - -
Net Debt 2022 - - -
P/E ratio 2022 20,6x
Yield 2022 -
Sales 2023 901 M - -
Net income 2023 352 M - -
Net Debt 2023 - - -
P/E ratio 2023 17,1x
Yield 2023 -
Capitalization 6 462 M 6 462 M -
Capi. / Sales 2022 9,04x
Capi. / Sales 2023 7,17x
Nbr of Employees 145
Free-Float 98,8%
More Financials
Company
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’... 
More about the company
Ratings of Halozyme Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about HALOZYME THERAPEUTICS, INC.
06/15TRANSCRIPT : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Heal..
CI
06/10Genmab Seeks $405 Million in New Arbitration With Janssen
MT
06/10Genmab Opens New Arbitration In Daratumumab License Dispute With Janssen
MT
06/08Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
PR
06/07Halozyme Therapeutics Launches Testosterone Replacement Therapy Drug Tlando
MT
06/07Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testostero..
PR
06/07Halozyme Therapeutics, Inc. Announces Commercial Launch of TLANDO, an Oral Treatment fo..
CI
05/26Goldman Sachs Raises Halozyme Therapeutics' Price Target to $60 From $48, Buy Rating Ke..
MT
05/24HALOZYME THERAPEUTICS : Completes Antares Pharma Acquisition - Form 8-K
PU
05/24HALOZYME THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Ac..
AQ
05/24Halozyme Completes Antares Pharma Acquisition
PR
05/23Halozyme Therapeutics, Inc. completed the acquisition of Antares Pharma, Inc..
CI
05/12Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition
MT
05/12Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
PR
05/11JMP Securities Raises Halozyme Therapeutics Price Target to $58 From $55, Maintains Mar..
MT
More news
News in other languages on HALOZYME THERAPEUTICS, INC.
06/10Genmab réclame 405 millions de dollars dans un nouvel arbitrage avec Janssen
06/10Genmab ouvre un nouvel arbitrage dans le différend sur la licence du daratumumab avec J..
06/07Halozyme Therapeutics lance le médicament Tlando pour le traitement de remplacement de ..
06/07Halozyme Therapeutics, Inc. annonce le lancement commercial de TLANDO, un traitement or..
05/23HALOZYME THERAPEUTICS, INC. (NASDAQG : HALO) a finalisé l'acquisition d'Antares Pharma, In..
More news
Analyst Recommendations on HALOZYME THERAPEUTICS, INC.
More recommendations
Chart HALOZYME THERAPEUTICS, INC.
Duration : Period :
Halozyme Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HALOZYME THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 46,90 $
Average target price 55,00 $
Spread / Average Target 17,3%
EPS Revisions
Managers and Directors
Helen I. Torley President, Chief Executive Officer & Director
Nicole LaBrosse Executive Director & Controller
Connie L. Matsui Chairman
Michael J. LaBarre Chief Technical Officer & Senior Vice President
Steve Knowles Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
HALOZYME THERAPEUTICS, INC.16.39%6 462
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574